Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction:

Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and efficacy are therefore urgently needed.

Problem Statement:

Traditional Bismuth Quadruple Therapy is effective but frequently associated with complex dosing schedules, high adverse event burden and poor patient compliance. Whether a simplified vonoprazan-based dual regimen can achieve comparable rescue eradication rates with better tolerability remained uncertain.

Summary:

This prospective randomized controlled trial evaluated a simplified dual regimen combining Vonoprazan and tetracycline as rescue therapy for H. pylori infection in patients with at least one prior eradication failure.

The study compared 14-day vonoprazan–tetracycline dual therapy against standard bismuth quadruple therapy in 350 patients.

The dual regimen achieved eradication rates that were noninferior to bismuth quadruple therapy across both modified intention-to-treat and per-protocol analyses, with eradication rates exceeding 90%.

Importantly, the simplified dual regimen demonstrated a major tolerability advantage. Treatment-emergent adverse events occurred far less frequently compared with quadruple therapy, and no patients discontinued treatment because of side effects.

Adherence was also significantly higher with dual therapy, likely reflecting reduced pill burden, simplified scheduling and improved gastrointestinal tolerability.

These findings are clinically important because rescue H. pylori therapy frequently fails not only because of antimicrobial resistance but also because patients struggle to complete complex multidrug regimens.

The study further reinforces the growing role of vonoprazan-based therapy in modern H. pylori management. Unlike traditional proton pump inhibitors, vonoprazan provides rapid, potent and sustained acid suppression, potentially improving antibiotic stability and bacterial eradication efficacy.

The results are especially relevant in regions with high clarithromycin and metronidazole resistance, where conventional salvage regimens often become increasingly difficult to optimize.

The use of tetracycline is also noteworthy because resistance rates remain relatively low globally compared with other commonly used antibiotics.

Clinically, the regimen offers an attractive rescue strategy that balances efficacy, simplicity and tolerability, which are critical determinants of real-world eradication success.

The findings additionally support an evolving treatment paradigm in H. pylori management favoring streamlined, high-potency acid suppression combined with fewer antibiotics rather than increasingly complex multidrug combinations.

Importantly, the open-label design represents a limitation, and the study population was derived from China, which may affect global generalizability because regional antimicrobial resistance patterns differ substantially.

Further studies comparing this regimen against rifabutin-based and susceptibility-guided rescue therapies will be important to define its position within future treatment algorithms.

Longer-term surveillance will also be needed to monitor emerging tetracycline resistance if widespread adoption occurs.

Overall, this trial demonstrates that vonoprazan–tetracycline dual therapy is an effective, simplified and better-tolerated rescue regimen for H. pylori infection, offering eradication efficacy comparable to bismuth quadruple therapy while substantially improving safety and adherence.